Atlas Antibodies' range of cancer antibodies are highly validated, showing high specificity and selectivity for their target proteins. These antibodies have been used for staining 48 normal human tissue samples and human cancer samples, covering the 17 most common cancer types and up to 12 patients for each cancer type.
The catalogue includes a wide range of PreciseA monoclonals and Triple A polyclonals for cancer stem cells, mechanisms in cancer, glioma, oncology biomarkers, epithelial-to-mesenchymal transition, GPCRS, colorectal and breast cancer.
The range includes antibodies for:
Why choose an Atlas antibody?
Validated by Enhanced Validation
Atlas Antibodies produce over 21,000 highly characterised primary antibodies, taking great care to validate for use in IHC, WB and ICC-IF. As an additional layer of security, they also perform enhanced validated on over 5,000 antibodies, using five methods of stringent validation.
Created by the Human Protein Atlas
The Triple A Polyclonal range is developed with the prestigious Human Protein Atlas project, with these antibodies validated in all major human tissues and organs, as well as 20 cancer tissues. In addition, each antibody in this range is supported with over 500 staining images.
Evidenced by science
Atlas Antibodies are used all over the world and referenced in thousands of scientific peer-reviewed papers.